JP2021513974A5 - - Google Patents
Info
- Publication number
- JP2021513974A5 JP2021513974A5 JP2020543512A JP2020543512A JP2021513974A5 JP 2021513974 A5 JP2021513974 A5 JP 2021513974A5 JP 2020543512 A JP2020543512 A JP 2020543512A JP 2020543512 A JP2020543512 A JP 2020543512A JP 2021513974 A5 JP2021513974 A5 JP 2021513974A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- sequence number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024017576A JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1802487.7 | 2018-02-15 | ||
| GBGB1802487.7A GB201802487D0 (en) | 2018-02-15 | 2018-02-15 | Cytokine combination therapy |
| PCT/EP2019/053890 WO2019158728A1 (en) | 2018-02-15 | 2019-02-15 | Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024017576A Division JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513974A JP2021513974A (ja) | 2021-06-03 |
| JP2021513974A5 true JP2021513974A5 (enExample) | 2022-03-09 |
| JP7808430B2 JP7808430B2 (ja) | 2026-01-29 |
Family
ID=61783635
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543512A Active JP7808430B2 (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
| JP2024017576A Pending JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024017576A Pending JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12030949B2 (enExample) |
| EP (1) | EP3752529A1 (enExample) |
| JP (2) | JP7808430B2 (enExample) |
| CN (1) | CN112041342B (enExample) |
| AU (1) | AU2019221627B2 (enExample) |
| CA (1) | CA3088734A1 (enExample) |
| GB (1) | GB201802487D0 (enExample) |
| IL (1) | IL276344A (enExample) |
| WO (1) | WO2019158728A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| CN111825766B (zh) * | 2019-10-31 | 2021-05-11 | 上海洛启生物医药技术有限公司 | 抗il-4r单域抗体及其应用 |
| WO2021249555A1 (en) * | 2020-06-12 | 2021-12-16 | Beijing Vdjbio Co., Ltd. | Fusion polypeptide |
| JP7743500B2 (ja) | 2020-08-05 | 2025-09-24 | シンセカイン インコーポレイテッド | Ｉｌ１０受容体結合性分子および使用方法 |
| WO2022031890A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Ifngr2 binding molecules and methods of use |
| EP4192489A4 (en) | 2020-08-05 | 2024-12-11 | Synthekine, Inc. | IL2RB-BINDING MOLECULES AND METHODS OF USE |
| US12540188B2 (en) | 2020-08-05 | 2026-02-03 | Synthekine, Inc. | IL10Rα/IL2Rγ synthetic cytokines |
| CN114075282B (zh) * | 2020-08-20 | 2024-01-02 | 南京融捷康生物科技有限公司 | Il-5的结合分子及其制备方法和应用 |
| KR102697769B1 (ko) * | 2020-09-14 | 2024-08-23 | 아주대학교산학협력단 | 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도 |
| CN113214394B (zh) * | 2020-10-30 | 2023-01-06 | 上海洛启生物医药技术有限公司 | 抗il5纳米抗体及其应用 |
| CN114605539B (zh) * | 2020-12-09 | 2024-01-02 | 南京融捷康生物科技有限公司 | 人源化的抗IL-4Rα单域抗体及其应用 |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| CN114805572B (zh) * | 2021-01-22 | 2022-12-13 | 上海济煜医药科技有限公司 | 抗原结合蛋白及其应用 |
| CN117138036A (zh) * | 2022-05-23 | 2023-12-01 | 南京融捷康生物科技有限公司 | 一种稳定的双特异性纳米抗体制剂 |
| CA3239182A1 (en) * | 2022-05-23 | 2023-11-30 | Zhipeng SU | Stable antibody preparation |
| CN120882743A (zh) * | 2023-03-02 | 2025-10-31 | 瑞韦博治疗公司 | 包含单特异性和双特异性非阻断性抗细胞因子抗体的基于细胞因子的疗法和方法 |
| CN116606375B (zh) * | 2023-07-03 | 2025-10-03 | 珠海瑞思普利医药科技有限公司 | 抗人白介素5纳米抗体及其应用 |
| TW202607036A (zh) * | 2024-07-19 | 2026-02-16 | 美商班布薩治療公司 | 多特異性結合劑及其用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| WO2009121847A2 (en) * | 2008-04-02 | 2009-10-08 | Apogenix Gmbh | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
| CN102361884A (zh) | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-2/抗-c-Met抗体 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| AU2011245117B2 (en) * | 2010-04-30 | 2015-03-12 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| JP2014511836A (ja) | 2011-03-25 | 2014-05-19 | グレンマーク ファーマシューティカルズ， エセ．アー． | ヘテロ二量体免疫グロブリン |
| GB2504139B (en) | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
| EP3517548A1 (en) | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| EP3553089A1 (en) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EA032681B1 (ru) | 2012-11-27 | 2019-07-31 | Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн | ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| HK1218930A1 (zh) | 2013-02-08 | 2017-03-17 | Abbvie Stemcentrx Llc | 新型多特异性结构 |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| WO2014151910A1 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| RS59354B1 (sr) | 2013-06-21 | 2019-10-31 | Sanofi Biotechnology | Postupci lečenja nosne polipoze davanjem il-4r antagonista |
| EP3041865A2 (en) | 2013-09-03 | 2016-07-13 | NovImmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| US20160251440A1 (en) | 2013-09-26 | 2016-09-01 | Ablynx N.V. | Bispecific nanobodies |
| BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| RU2609627C2 (ru) | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| JP6696982B2 (ja) | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| US20160272706A1 (en) * | 2015-01-12 | 2016-09-22 | Medimmune Limited | Il-13 binding proteins and uses thereof |
| MA41375A (fr) | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| GB201707484D0 (en) | 2017-05-10 | 2017-06-21 | Argenx Bvba | Method of preparing ph-dependent antibodies |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
-
2018
- 2018-02-15 GB GBGB1802487.7A patent/GB201802487D0/en not_active Ceased
-
2019
- 2019-02-15 US US16/966,237 patent/US12030949B2/en active Active
- 2019-02-15 JP JP2020543512A patent/JP7808430B2/ja active Active
- 2019-02-15 CN CN201980025923.3A patent/CN112041342B/zh active Active
- 2019-02-15 AU AU2019221627A patent/AU2019221627B2/en active Active
- 2019-02-15 CA CA3088734A patent/CA3088734A1/en active Pending
- 2019-02-15 WO PCT/EP2019/053890 patent/WO2019158728A1/en not_active Ceased
- 2019-02-15 EP EP19715814.0A patent/EP3752529A1/en active Pending
-
2020
- 2020-07-28 IL IL276344A patent/IL276344A/en unknown
-
2024
- 2024-02-08 JP JP2024017576A patent/JP2024063016A/ja active Pending
- 2024-06-28 US US18/758,267 patent/US20240352138A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024063016A5 (enExample) | ||
| AU2022241522B2 (en) | Bispecific antibody to a-syn/igf1r and use thereof | |
| EP4541813A2 (en) | Method of preparing ph-dependent antibodies | |
| US20200399382A1 (en) | Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r | |
| JP2021520825A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2010538608A5 (enExample) | ||
| JP2021520825A (ja) | ガレクチン−１０抗体 | |
| JP2008527989A5 (enExample) | ||
| JP6898251B2 (ja) | 組換え抗体分子の単量体化方法 | |
| WO2019195313A1 (en) | Anti-vegf antagonist and pedf agonist constructs and uses thereof | |
| AU2021328375A1 (en) | Anti-PAR-2 antibodies and methods of use thereof | |
| ES3053942T3 (en) | Anti-stem cell factor antibodies and methods of use thereof | |
| CN106905431A (zh) | 抗人补体d因子的单克隆抗体及其用途 | |
| CA3096791A1 (en) | Cell engaging binding molecules | |
| CA3200847A1 (en) | Multi-specific antibodies and antibody combinations | |
| CN114846026A (zh) | 对人il-13和il-17具有结合特异性的多特异性抗体 | |
| JP2024523514A5 (enExample) | ||
| TW202525846A (zh) | 抗ｉｌ—１３多特異性抗體構築體及其用途 | |
| KR20260051068A (ko) | Enpp3 및 cd3 결합제 및 이의 사용 방법 | |
| US20230374148A1 (en) | Binding molecules that multimerise cd45 | |
| JP2024523034A5 (enExample) | ||
| CA3200836A1 (en) | Antibodies against interleukin-22 | |
| CN120554510B (zh) | 抗钙粘蛋白-17的双表位抗体及采用其制备的抗体药物偶联物 | |
| US20240117056A1 (en) | Epidermal growth factor receptor variant iii antibodies |